(Q57413490)

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Thiazolidinediones and Heart Failure: A teleo-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

A meta-analysis of the effect of thiazolidinediones on blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for th

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Use of thiazolidinediones and fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

PPAR-gamma regulates osteoclastogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Anemia in diabetes: marker or mediator of microvascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Diabetic macular edema associated with glitazone use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.5.579